{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:28:54Z","timestamp":1777508934620,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.msard.2025.106422","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T21:13:07Z","timestamp":1743801187000},"page":"106422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Epidemiology of aquaporin-4 seropositive neuromyelitis optica spectrum disorder in the Alicante health area, Spain: A population-based study"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7550-6239","authenticated-orcid":false,"given":"Luis","family":"Moreno-Navarro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Farrerons-Llopart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Lorenzo-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Ruiz-Escribano-Menchen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel P.","family":"Sempere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106422_bib0001","series-title":"Radiation and Ozone. Ultraviolet Radiation [Internet","year":"2024"},{"key":"10.1016\/j.msard.2025.106422_bib0002","series-title":"Age Standardization of Rates: a New WHO Standard","first-page":"1","author":"Ahmad","year":"2001"},{"issue":"3","key":"10.1016\/j.msard.2025.106422_bib0003","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106422_bib0004","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/13524585221113272","article-title":"Association between infections, the microbiome, vaccination, and neuromyelitis optica spectrum disorder","volume":"29","author":"Carnero-Contentti","year":"2023","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2025.106422_bib0005","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106422_bib0006","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1212\/WNL.0000000000001001","article-title":"Protective environmental factors for neuromyelitis optica","volume":"83","author":"Graves","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106422_bib0007","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the neuromyelitis optica study group (NEMOS). Part II: attack therapy and long-term management","author":"K\u00fcmpfel","year":"2023","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2025.106422_bib0008","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2025.106422_bib0009","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O'Connell","year":"2020","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"10.1016\/j.msard.2025.106422_bib0010","series-title":"Revision of the European Standard Population: Report of Eurostat's task Force","author":"Pace","year":"2013"},{"issue":"24","key":"10.1016\/j.msard.2025.106422_bib0011","doi-asserted-by":"crossref","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2025.106422_bib0012","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ene.14079","article-title":"A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary","volume":"27","author":"Papp","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106422_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2025.106422_bib0014","first-page":"131","article-title":"Whole grains and legumes consumption in association with neuromyelitis optica spectrum disorder odds","volume":"20","author":"Rezaeimanesh","year":"2021","journal-title":"Curr. J. Neurol."},{"key":"10.1016\/j.msard.2025.106422_bib0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/13524585231151953","article-title":"A national case-control study investigating demographic and environmental factors associated with NMOSD","volume":"29","author":"Rotstein","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106422_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103258","article-title":"Neuromyelitis optica spectrum disorders: a nationwide Portuguese clinical epidemiological study","volume":"56","author":"Santos","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"14","key":"10.1016\/j.msard.2025.106422_bib0017","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates","volume":"24","author":"Sep\u00falveda","year":"2018","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2025.106422_bib0018","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/01616412.2021.1952741","article-title":"Incidence and prevalence of neuromyelitis optica spectrum disorders in Slovakia","volume":"44","author":"Szilasiov\u00e1","year":"2022","journal-title":"Neurol. Res."},{"key":"10.1016\/j.msard.2025.106422_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102879","article-title":"Population-based head-to-head comparison of the clinical characteristics and epidemiology of AQP4 antibody-positive NMOSD between two European countries","volume":"51","author":"Viktoria","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2025.106422_bib0020","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J. Neurol. Neurosurg. Psych."},{"issue":"2","key":"10.1016\/j.msard.2025.106422_bib0021","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2025.106422_bib0022","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"37","key":"10.1016\/j.msard.2025.106422_bib0023","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027234","article-title":"A preliminary study of association of cigarette smoking with risk of neuromyelitis optica spectrum disorder","volume":"100","author":"Yang","year":"2021","journal-title":"Medicine"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T21:34:49Z","timestamp":1747258489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825001646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":23,"alternative-id":["S2211034825001646"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106422","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology of aquaporin-4 seropositive neuromyelitis optica spectrum disorder in the Alicante health area, Spain: A population-based study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106422"}}